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Abstract:  
 
Background: First Episode Psychosis (FEP) patients who use cannabis 
experience more frequent psychotic and euphoric intoxication experiences 
compared to controls. It is not clear whether this is consequent to patients 
being more vulnerable to  the effects of cannabis use or to their heavier 
pattern of use. We aimed to determine whether extent of use predicted 
psychotic-like and euphoric intoxication experiences in patients and controls 
and whether this differs between groups.  
 
Methods: We analysed data on patients who had ever used cannabis 
(n=655) and controls who had ever used cannabis (n=654) across 15 sites 
from six countries in the EU-GEI study (2010-2015). We used multiple 
regression to model predictors of cannabis-induced experiences and to 
determine if there was an interaction between caseness and extent of use. 
 
Results: Caseness, frequency of cannabis use and money spent on cannabis 
predicted psychotic-like and euphoric experiences (p≤0.001).  For psychotic-
like experiences there was a significant interaction for caseness x frequency 
of use (p<0.001) and caseness x money spent on cannabis (p=0.001) such 
that FEP patients had increased experiences at increased levels of use 
compared to controls. There was no significant interaction for euphoric 
experiences (p>0.5). 
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Conclusions: FEP patients are particularly sensitive to increased psychotic-
like, but not euphoric experiences, at higher levels of cannabis use compared 
to controls. This suggests a specific psychotomimetic response in FEP 
patients related to heavy cannabis use. Clinicians should enquire regarding 
cannabis related psychotic-like experiences and advise that lower levels of 
cannabis use are associated with less frequent psychotic-like experiences. 
 
Keywords: schizophrenia, psychotic-like experiences, psychotomimetic, 
substance abuse 
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Association of extent of cannabis use and psychotic like 
intoxication experiences in a multi-national sample of First 
Episode Psychosis patients and controls 
 
Introduction 
There is consistent evidence supporting  an association between cannabis 
use and later psychosis(Myles, Myles, & Large, 2015). Further,  patterns of 
cannabis use in  first episode psychosis (FEP) patients are greater in terms of 
quantity, frequency and potency of cannabis used compared to controls from 
the same population(Di Forti et al., 2015; Hasan et al., 2019; Marconi, Di 
Forti, Lewis, Murray, & Vassos, 2016). There is converging evidence that 
cannabis is a component cause of psychotic disorder with well-replicated 
evidence of dose-response effects on psychotic outcomes(Marconi et al., 
2016; Moore et al., 2007; Murray & Di Forti, 2016; Ortiz-Medina et al., 2018; 
Schoeler et al., 2016). 
 
When discussing psychosis and cannabis use, it is important to differentiate 
between psychotic-like experiences (PEs) and clinical psychotic disorder. 
Clinical psychotic disorder is relatively rare (incidence 21.4-26.6 per 100,000 
person years(Jongsma et al., 2018; Jongsma, Turner, Kirkbride, & Jones, 
2019)) whereas PEs are common and self-limiting (incidence 3,000 per 
100,000 person-years(J van Os, Linscott, Myin-Germeys, Delespaul, & 
Krabbendam, 2009)) but can be a harbinger of more serious 
disorder(Werbeloff et al., 2012). However, the usual instruments for 
measuring PEs, such as the Peter’s Delusions Inventory (PDI) or the 
Community Assessment of Psychic Experience (CAPE), either do not 
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specifically index drug-induced experiences as  part of the intoxication 
state(Stefanis et al., 2002) or specifically exclude them(E. Peters, Joseph, 
Day, & Garety, 2004; E. R. Peters, Joseph, & Garety, 1999).  
 
Recreational drugs such as cannabis are used primarily for their immediate 
psychoactive effects. Factor analytic approaches have clustered cannabis 
intoxication experiences into psychotic-like experiences (cPLEs) and euphoric 
experiences (cEEs)(E. J. Barkus, Stirling, Hopkins, & Lewis, 2006a; Quinn, 
Wilson, Cockshaw, Barkus, & Hides, 2016). cPLEs (sometimes called 
psychotomimetic experiences) are worthy of study in their own right as a 
model for psychotic disorder. cPLEs are increased in patients versus 
controls(Bianconi et al., 2016; D’Souza et al., 2005); increased in those with 
schizotypy and those at risk of schizophrenia(E. J. Barkus et al., 2006a; 
Stirling et al., 2008; Vadhan, Corcoran, Bedi, Keilp, & Haney, 2017). cPLEs 
may predict cessation of use in a non-clinical sample(Sami, Notley, 
Kouimtsidis, Lynskey, & Bhattacharyya, 2018)  whereas patients with 
psychotic disorders report using cannabis for affect regulation and 
socialization, despite awareness that cannabis has a detrimental effect on 
positive symptoms of psychosis(Dekker, Linszen, & De Haan, 2009).  
 
One study to date has reported that patients experience both cPLEs and 
cEEs more frequently than controls but this did not take into account 
increased use in patients(Bianconi et al., 2016).   Given that both increased 
rates of cannabis use and increased cannabis experiences are seen in FEP, it 
is not yet clear how these relate to each other and whether this differs from 
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that of controls. No study to date has examined specifically the relationship 
between extent of use, cannabis experiences and psychotic disorder. 
 
We therefore studied cannabis experiences in a large international sample of 
FEP patients and control lifetime cannabis users. To index these experiences 
we used the Cannabis Experiences Questionnaire an instrument specifically 
developed to assess retrospective cannabis experiences(E. J. Barkus et al., 
2006a; Stirling et al., 2008). We hypothesised that: (a) we would replicate the 
finding of increased cPLEs and cEEs in FEP patients versus controls; (b) 
extent of use (as indexed by frequency of use, money spent on cannabis, and 
potency) would be associated with more frequent cannabis-induced 
experiences when adjusted for confounders; and (c) this effect would differ 
between cases and controls: specifically that both cPLEs and cEEs would be 
more affected by heavy use in FEP patients versus controls. We included 
THC potency as a proxy of the dose of Δ⁹-tetrahydrocannabinol the primary 
psychomimetic constituent in cannabis(Morrison et al., 2009).	
 
Methods: 
 
The European network of national networks studying gene environment 
interactions in schizophrenia (EU-GEI) study is a multi-centre study 
comprising several workpackages(Jim Van Os et al., 2014). Workpackage 2 
comprises a 17 centre study across six countries (United Kingdom, Holland, 
Spain, France, Italy,  Brazil) on first episode psychosis. Local Research Ethics 
Committee approval was obtained from each area. 
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Sample selection: Patients and controls were recruited between May 2010 
and May 2015. Patients were identified by trained EUGEI researchers across 
the 17 sites and invited by clinical teams to participate. For patients inclusion 
criteria were: (i) age 18-64; (ii) presentation with First Episode psychosis 
(ICD-10 F20-33); and (iii) residence within each defined locality. Exclusion 
Criteria were: (i) organic psychosis (ICD-10:	F09); (ii) psychosis due to acute 
intoxication (ICD-10: F1X.5) and (iii) previous contact with mental health 
services for psychosis. For full diagnostic data see sTable 1 (Supplement). 
 
Controls were recruited using a quota strategy derived from local 
demographic data to be representative for age, sex and ethnicity of the 
population at risk for each site. In order to sample controls in the first instance 
we undertook random sampling a) from lists of all postal addresses and b) 
from GP lists from randomly selected surgeries. The EUGEI study aimed to 
over-sample certain groups (e.g. young men) using direct approaches such as 
local avertismenets and leaflets at local shops and community centers. 
Controls were excluded if they had received a diagnosis or treatment for 
psychotic disorder.  
 
Further details of the EUGEI study have previously been described(Jongsma 
et al., 2018). For the purpose of this study, analysing cannabis experiences, 
we only analysed data from participants (both patients and controls) who 
reported having ever used cannabis (lifetime use). 
 
We did not use data from two centres: Maison-Blanche (France) as this centre 
did not collect controls and Verona (Italy) as cannabis use data were not 
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complete. We excluded 12 cases (1.8%) who were classified as having non-
psychotic illness from the Diagnosis and Statistical Manual IV (DSM-IV) 
Operational Criteria Checklist (OPCRIT) screening of medical records. 
 
Measures:  
Demographics: data were collected on age, sex, ethnicity, site, country and 
years of education.  
Cannabis use: A modified version of the Cannabis Experiences Questionnaire 
was used to collect cannabis use variables and cannabis experiences data(E. 
J. Barkus, Stirling, Hopkins, & Lewis, 2006b). This is a researcher 
administrated measure which collects self-reported data on: age of first use, 
frequency of use (categories: every day; more than once a week; a few times 
a month; a few times each year; only once or twice), average money spent in 
a week (categories: less than €2.50; €2.50-€5.00; €5.00-€10.00, €11.00-
€15.00; €16.00-€20.00; and 6 above €20).  
 
Potency: Since there is geographical variation in type of cannabis used we 
used an approach to determine users of low potency and high potency 
cannabis as has been reported before in the EUGEI study. Breifly participants 
were asked to name the strain they most often used in their own language. 
Strains were compared to mean reported THC concentration  from published 
data from European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA)(European Monitoring Centre for Drugs and Drug Addiction, 2016). 
High potency cannabis was categorized as THC>=10%: including UK home-
grown skunk/sensimilla UK Super Skunk, Italian home-grown skunk/sensimilla 
, Italian Super Skunk, the Dutch Nederwiet, Nederhasj and geimporteerde 
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hasj, the Spanish and French Hashish (from Morocco); or ‘low potency’ with 
mean THC<10% including: hash/resin from UK and Italy, imported herbal 
cannabis from UK, Italy, Spain and France, Brazilian marijuana and hash and 
the Dutch Geimporteerde Wiet . For further details see (Di Forti et al., 2019) 
 
Other drug use:  We collected data on number of other drugs used, number of 
cigarettes smoked per day and units of alcohol consumed daily.  
Cannabis Experiences: Frequency of nine intoxication experiences - six 
cPLEs (feeling fearful; feeling crazy or mad; feeling nervy; feeling suspicious; 
hearing voices; seeing visions); and three cEEs (feeling happy; understanding 
the world better; being full of plans or ideas) were rated on a 5 point Likert 
scale: (0 rarely or never, 1 from time to time, 2 sometimes 3 more often than 
not, 4 almost always). These experiences were chosen as previous factor 
analytic approaches in development of the Cannabis Experiences 
Questionnaire showed that these experiences load significantly onto 
respective subscales to index psychotic-like experiences and pleasurable 
effects(E. Barkus & Lewis, 2008; Stirling et al., 2008).  
 
Statistical Analysis: Scores were obtained for cPLEs and cEEs by simple 
summation, as previously undertaken(E. J. Barkus et al., 2006b; Sami et al., 
2018). As there were half as many euphoric experiences items as psychotic 
like experiences items, the scores for euphoric experiences were doubled 
rendering a scale of between 0 and 24 for both cPLEs and cEEs. Since such 
experiences can be conceptualised to index an underlying continuum both 
cPLEs and cEES were treated as continuous variables.  
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Extent of use was indexed primarily by frequency of cannabis use and by 
potency. In further sensitivity analysis we replaced these with money spent on 
cannabis use. We calculated Pearson’s Correlation coefficients to test 
whether the extent of use variables were correlated. 
 
Demographics and substance use: We ascertained differences between 
demographic (age at assessment, sex, ethnicity, years in education, site) and 
cannabis use parameters (age of first use, frequency of use, money spent per 
week, potency, duration of use, lifetime and 12 month dependence) and other 
drug use parameters (cigarettes per day, units of alcohol in a day, and other 
drugs ever used (excluding cannabis, alcohol, tobacco and caffeine)) using t-
tests for continuous variables and chi-squared for categorical variables. 
 
Main Analysis:  
We undertook to test the three hypotheses in a regression analyses 
framework. To test hypothesis (a) that caseness predicts experience: we 
regressed cannabis experiences (cPLEs and cEEs) as the dependent 
variables and caseness as the independent variables. To test hypothesis (b) 
that extent of use predicts experiences: we regressed cannabis experiences 
as the dependent variables and the extent of use variables as the 
independent variables. As the extent of use variables we entered frequency of 
cannabis use, and THC potency into separate models. These two variables 
(frequency of use and potency) were chosen to primarily index extent of use 
as they are both related to the extent of cannabis exposure but are distinct 
behaviours (for example one can use very frequently but at low potency). To 
test hypothesis (c): that there is an interaction between caseness and extent 
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of use on cannabis experiences: we regressed cannabis experiences as the 
dependent variables and  caseness and the extent of use variables alongside 
the interaction of caseness x extent of use. In all models we entered cPLEs as 
a regressor when the dependent variable was cEEs and cEEs as a regressor 
when the dependent variable was cPLEs to ensure that the predictors 
identified for relationships were independent of the other experience. 
 
In sensitivity analyses for hypothesis (b) and (c) we ran the same regressions 
models using money spent on cannabis use rather than the frequency or 
potency variables. 
 
We undertook a further sensitivity analysis to adjust for confounders. 
Psychotic like experiences may be explained by a number of putative other 
confounders other than caseness or extent of use. We hence adjusted for 
firstly demographic variables (age, sex, ethnicity) in secondary models and 
further to this substance misuse confounders in tertiary models (number of 
other drugs ever used, tobacco use and alcohol use) as other substance 
misuse may arguably be related to cannabis induced experiences to see if 
interaction effects survived putative confounders.  
 
Finally we undertook a supplementary analysis to see if interactions for other 
classes of drugs were present on cPLEs. This analysis did not change the 
main findings reported in the manuscript and is reported in full in the 
Supplement. 
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cPLEs and cEEs demonstrated positive skew (cEEs 0.612, cPLEs 2.231). 
Because of violations of homoscedasticity in regression models we undertook 
all analyses using the robust regression option in STATA. For the purpose of 
estimation of 95% Confidence Intervals (see Figure 1)  we applied 
bootstrapping to inferential tests using 1000 samples and bias corrected and 
accelerated confidence intervals. 
 
Missing data: Missing data rates are shown in Supplementary Table 4. cPLEs 
were available for 598/655 (91.3%) cases and 615/654 (94.0%) controls 
whereas cEEs scores were available for 602/655 (91.9%) cases and 616/654 
(94.2%) controls.To ensure that results were not the result of systematic 
missing data, missing data was imputed using imputation analysis with 
chained equations(Azur, Stuart, Frangakis, & Leaf, 2012) for cPLEs and and 
cEEs as outcome variables, independent and auxillary variables. 29 variables 
were included in the imputation model, including cannabis use variables (age 
of first use, social use, frequency, money spent, diagnosis of misuse), other 
drug use variables (tobacco use, alcohol use, number of other drugs used), 
and demographic variables (sex, age, ethnicity, site, psychosis diagnosis). 
Fifty datasets were imputed with 10 cycles.  
 
Regression and main analyses were run using the imputed dataset to account 
for missing data. Exploratory pairwise correlation between the extent of use 
variables was undertaken listwise since pairwise correlation is not available 
using the mi estimate command in STATA. Data was analysed using STATA 
version 15.  
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Results  
 
Data were available for 1035 cases patients and 1382 controls. 655 cases 
(63.3% of all cases) and 654 controls (47.3% of all controls) reported ever use 
of cannabis and data analysis was restricted to them.  
 
Baseline demographics: 
Cases were significantly more likely than controls to be male, younger and 
have had fewer years of education (see Table 1a). As expected, cases were 
more likely to have started using cannabis younger, more likely to have used 
more frequently, to have used more other drugs, and smoked more cigarettes 
per day (see Table 1b). Detailed diagnostic, ethnicity and site data are 
presented in Supplementary Tables 1-3. 
 
Extent of use: 
As expected the variables indexing extent of use were significantly correlated. 
Frequency of use weakly correlated with dichotomised potency (r=0.121, 
p=0.001). Frequency of use strongly correlated with with money spent on 
cannabis per week (r=0.703, p<0.001) whereas potency moderately 
correlated with money spent on cannabis (r=0.211, p<0.001). 
 
Caseness by frequency of use on cPLEs and cEEs (hypothesis a): 
As hypothesised caseness predicted cPLEs independent of cEEs (b=0.826, 
t=7.86, p<0.001) and predicted cEEs independent of cPLEs (b=0.840, 
t=4.40,p<0.001) such that patients had both more frequent psychotic-like and 
euphoric experiences than controls.  
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Extent of use as a predictor of cPLEs and cEEs (hypothesis b): 
As hypothesised extent of use predicted cPLEs independent of cEEs whether 
the extent of use variable was frequency of use (b=0.502, t=6.18, p<0.001), or 
potency (b=0.543, t=2.36, p=0.019) such that increased extent of use 
predicted increased psychotic-like experiences. Similarly frequency of use 
predicted cEEs independent of cPLEs (b=2.17, t=21.46, p<0.001) but this was 
not the case with potency (b=0.210, t=0.55, p=0.58). 
 
Sensitivity analysis (hypothesis b): 
For cPLEs results were the same when extent of use was indexed by money 
spent on cannabis per week (b=0.397, t=6.17, p<0.001) such that money 
spent predicted increased psychotic-like experiences. Similarly for cEEs 
increased money spent on cannabis predicted cEEs independent of cPLEs 
(b=1.24, t=13.64, p<0.001). 
 
Interaction Effects (hypothesis c): 
Model parameters for caseness by extent of use and their interaction on 
predicting cannabis psychotic-like experiences can be seen in Table 2 and 
caseness x extent of use scores for mean experiences are shown in Figure 1.  
 
Caseness x frequency of use on cPLEs: 
There was a significant caseness effect (b=1.354, t=6.20, p=0.001); a 
significant effect for increased frequency of cannabis use (b=0.794, t=4.74, 
p<0.001); and a significant interaction between group and frequency such that 
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increasing frequency was associated with increased difference in cPLEs 
between cases and controls (b=0.229, t=3.49, p=0.001).  
 
Caseness x potency on cPLEs: 
There was no significant effect of caseness (p=0.676); but an effect for 
potency such that increased potency was associated with increased cPLEs 
(b=1.241, t=2.28, p=0.023); and a significant interaction for caseness by 
potency (b=0.438, t=2.04, p=0.042).  
 
Caseness x extent of use variables on cEEs: 
There was evidence for increased euphoric experiences as cannabis use 
increased frequency (b=2.152, t=9.44, p<0.001) but not for potency (p=0.935). 
There was no significant interaction for either frequency or potency of 
cannabis use x caseness for cEEs as the dependent variable.  
 
Sensitivity analysis (hypothesis c): 
Caseness x money spent on cPLEs: There was no significant effect of 
caseness (p=0.112); but there was a significant effect for money spent such 
that cPLEs increased with more money spent (b=0.591, t=4.56, p=0.001); and 
a significant interaction between caseness and money spent such that more 
money spent was associated with increased difference in cPLEs between 
cases and controls (b=0.177, t=3.29, p=0.001).  
Caseness x extent of use variables on cEEs: There was evidence for 
increased euphoric experiences as cannabis use increased for money spent 
(b=1.109, t=5.75, p<0.001). There was no significant interaction for any of the 
extent of use variables x caseness for cEEs as the dependent variable.  
	 18	
 
Sensitivity analysis: Adjustment for demographic and substance use 
covariates: 
In secondary models we adjusted models for cPLEs as the dependent 
variables for demographic covariates: the interaction terms remained 
significant for caseness x frequency of use (b=0.207, t=3.19, p=0.001); 
caseness x money spent on cannabis (b=0.163, t=3.07, p=0.002); caseness x 
potency (b=0.446, t=2.08, p=0.038). In tertiary models we additionally 
adjusted for substance misuse covariates: the interaction terms remained 
significant for caseness x frequency of use (b=0.208, t=3.23, p=0.001) and 
caseness x money spent on cannabis (b=0.176, t=3.30, p=0.001); caseness x 
potency (b=0.441, t=2.08, p=0.038). We conclude that the caseness x extent 
of use interaction for increased cPLEs for patients versus controls is robust to 
a number of demographic and substance use confounders. 
 
Discussion: 
 
To our knowledge, this represents the largest case-control study with 
extensive cannabis data in First Episode Psychosis ever undertaken. We  (a) 
replicate the finding that cannabis intoxication experiences are more frequent 
in patients compared to controls; (b) show that extent of use as indexed by 
frequency of use and money spent on cannabis per week predict these 
experiences and (c) show that there is an interaction between caseness x 
frequency and caseness x money spent such that increasing levels of use are 
associated with more frequent psychotic-like experiences (but not euphoric 
experiences) in patients compared with controls. Importantly our findings are 
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robust to a number of putative  confounders including age, sex, gender and 
other substance use which would not explain any of these. Additionally we 
observe that these findings remains after accounting for various comorbid 
substance use parameters.  
 
Importantly, these findings indicate that cannabis related experiences change 
as a function of extent of use. The Cannabis Experiences Questionnaire 
provides a measure of experiences as a proportion of total cannabis use, 
rather than a simple count of total experiences. A maximal score for cPLEs 
indicates that all six psychotic like experiences were experienced every time 
cannabis was used whereas a minimal score indicates that these experiences 
were never or rarely experienced, irrespective of total number of times used.  
Hence higher scores indicate that the experience changes rather than simply 
indicating an increased total number of experiences due to increased number 
of times that cannabis is used.  
 
Although not the main purpose of this analysis we also found of interest that a 
history of crack cocaine and inhalant abuse are associated with an increase in 
cannabis induced psychotic experiences whereas such experiences appear 
less frequent in the context of opiate abuse (see Supplement for full details). 
This may indicate that there is a cross sensation of drugs of abuse  and is 
consistant with with previous literature in which whereas cannabis and 
cocaine use are synergistic for psychosis experiences(C. Roncero et al., 
2013) whereas opiate withdrawal is associated with psychosis 
experiences(Casado-Espada et al., 2019; Weibel, Mallaret, Bennouna-
Greene, & Bertschy, 2012), but this does not influence our main results. 
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This study extends previous work(Bianconi et al., 2016) by showing that 
extent of use is a key predictor of psychotic-like experiences and that FEP 
patients and controls have divergent experiences with increasing extent of 
use. Interestingly, the same relationship  does not hold for euphoric 
experiences as cEEs scores, when stratified by extent of use, are well-
matched between cases and controls. This suggests that specific 
mechanisms underlie the cannabis-related increases of psychotic-like 
experiences which may be related to genetic predisposition and may further 
support a GxE interaction as has been demonstrated on cannabis use with 
the risk of schizophrenia spectrum disorder(Guloksuz et al., 2019). One 
putative mechanism to be examined is that variation in the DRD2 and possibly 
AKT1 genes may render cases more likely to develop postsynaptic 
supersensitivity(Colizzi et al., 2015; Morgan, Freeman, Powell, & Curran, 
2016).  Further work is needed to identify the specific genetic mechanisms 
which interact with increased extent of use.  
 
Perhaps somewhat surprisingly we do not find the increased levels of use are 
associated with reduced euphoric experiences which would have been 
consistant with tolerance at heavier levels of use. Rather we find the 
relationship to indicate the opposite direction. There could be two possible 
explanations to this: either that repeated cannabis use is associated with 
increased sensitisation rather than tolerance to such experiences, or 
conversely that the association exists because individuals who have more 
euphoric experiences are more likely to use heavier amounts of cannabis. 
Further work is required to disentangle these two possibilities. 
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Strengths and Limitations: 
The particular strengths of this study are (i) the sample size and (ii) the 
international sample. The limitations include: (i) the cross-sectional design, (ii) 
the use of self report measures and (iii) the lack of laboratory tests of potency.  
 
The cross-sectional design precludes interpretation about temporal sequence 
of associations, which means it is difficult to disentangle whether extent of use 
causes enhanced experience or vice-versa.  Euphoric experiences (cEEs) are 
likely to drive use whereas this is not the case for psychotic-like experiences 
(cPLEs) which have previously been shown to be associated with subsequent 
discontinuing use(Sami et al., 2018; Valmaggia et al., 2014). Furthermore in 
the case of cPLEs we included cEEs as a covariate in the model to regress 
out the association with euphoria. This may tentatively suggest a role for 
sensatisation to increasing levels of cannabis use for cPLEs in FEP. 
 
Both exposure and outcome measures were based on self-report. It is 
possible that because cannabis can be amnestic in nature exposure to 
cannabis may be misreported. However the relationships we report were 
similar for both frequency of cannabis use and money spent on cannabis per 
week (and it is arguable whether money spent is a more salient indicator of 
use than frequency of use) which increase our confidence in reporting these 
relationships. There are limited methods to determine extent of use over a 
longer period. Hair samples can provide an estimate of use over three 
months, but have been shown to be unreliable in a major observational 
study(Taylor, Sullivan, Ring, Macleod, & Hickman, 2017). Moreover, self-
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report (but not hair) measures of cannabis use were found to predict acute 
psychotomimetic responses to cannabis(Curran et al., 2018). Additionally, 
self-reported data on cannabis potency is associated with its concentration of 
THC measured in the laboratory(Freeman et al., 2014) The outcome 
measures, although self-reported, were based on a considerable body of work 
validating cannabis experiences in non-clinical, although not in clinical 
populations(E. J. Barkus et al., 2006b; Quinn et al., 2016).  Another limitation 
is that the psychotic-like experiences were rated retrospectively rather than as 
state measures (e.g. in an experimental design administering THC).  
On the other hand, a strength of utilising retrospective self-report measures is 
that these are the experiences patients report to their clinicians during routine 
consultations. There were several differences between cases and controls, 
but the results persisted after adjusting for a wide variety of confounders. 
Perhaps most importantly cEEs were the same  between patients and 
controls when accounted for extent of use: this indicates differences in cPLEs 
between FEP and controls to be specific to intrinsic biological differences 
between groups rather than to other confounders. One further limitation is that 
we did not account for non-psychosis comorbidities such as ADHD which may 
be synergestic with substance use for a psychotic outcome, as has been 
shown in the context of cocaine dependence(Carlos Roncero et al., 2013). 
This could be undertaken in future studies. 
 
Clinical implications: 
We consider this study to have a number of important findings in the clinical 
context. Although easily elicitable, clinicians do not routinely inquire about 
cPLEs in the clinical context. Our study suggests there are important 
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differences between FEP patients and controls. Firstly our study adds to 
previous work(Bianconi et al., 2016), that patients experience cPLEs more 
frequently than controls. Secondly our work indicates that lower extent of use 
is associated with decreased cPLEs. This is in line with evidence suggesting 
that FEP who continue to use cannabis, especially daily high potency 
experience more relapses and worse clinical outcome than those who stop 
after illness onset(Schoeler et al., 2016). Thirdly we show that FEP patients 
are unlikely to derive greater euphoric effects compared to controls at 
increased levels of use, despite more frequent psychotic-like effects. In the 
absence of longtitudinal data we are unable to definitively determine whether 
change in use effects experiences. However in the interim patients and 
particularly those with profound cPLEs should be advised that lower levels of 
use are associated with fewer psychotic-like experiences;  and be advised 
that for high-potency cannabis there is limited evidence of added euphoric 
effect. 
 
Taken together we have shown that extent of cannabis use is associated with 
enhanced psychotic-like but not euphoric experiences in First Episode 
Psychosis patients compared to controls. This may suggest a Gene x 
Evidence interaction for extent of use and genetic risk for psychosis on 
cannabis experiences. Further research should aim to determine the 
biological mechanism underpinning differences between patients and 
controls. 
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Table 1a: Baseline characteristics between cases and controls 
 
 Case Controls p-Value 
Male 
Missing 
475 (72.5%) 
nil 
355 (54.3%) 
nil 
<0.001 
White 
Missing 
415 (63.6%) 
nil 
547 (83.8%) 
1 (0.2%) 
<0.001 
Age at first 
contact (x̄) 
Missing 
28.07 
 
nil 
  
Age at 
assessment (x̄) 
Missing 
28.51 
 
nil 
34.30 
 
1 (0.2%) 
<0.001 
Years in 
Education 
Missing* 
13.31 
 
12 (1.8%) 
15.69 
 
2 (0.3%) 
<0.001 
 
Table 1b: Comparison of Cannabis use patterns between cases and 
controls 
 
 Case Controls p-Value 
Age first tried cbs 
(x̄) 
 
Missing* 
 
16.91 
 
15 (2.2%) 
 
17.90 
 
nil 
 
<0.001 
Frequency of cbs 
use 
Once or twice 
Few times year 
Few times month 
>Once a week 
Every day 
 
Missing* 
 
 
108 (16.9%) 
65 (10.2%) 
63 (9.8%) 
110 (17.2%) 
294 (45.9%) 
 
15 (2.3%) 
 
 
240 (36.8%) 
120 (18.4%) 
100 (15.3%) 
100 (15.3%) 
93 (14.2%) 
 
1 (0.2%) 
 
 
 
 
 
<0.001 
Money Spent per 
week on cbs 
< €2.50 
€2.50-€5.00 
€6-€10 
€11-€15 
€16-€20 
>€20 
Missing 
 
 
217 (37.0%) 
52 (8.8%) 
80 (13.5%) 
36 (6.1%) 
39 (6.6%) 
170 (28.6%) 
61 (9.3%) 
 
 
415 (68.4%) 
58 (9.6%) 
42 (6.9%) 
25 (4.1%) 
24 (4.0%) 
43 (7.1%) 
47 (7.2%) 
 
 
 
 
 
 
 
<0.001 
Use of high 
potency cbs 
Missing 
 
291 (55.5%) 
131 (20.0%) 
 
223 (43.1%) 
136 (20.8%) 
 
<0.001 
Mean Duration of 
cbs use (years) 
Missing 
9.41 
 
18 (2.7%) 
9.82 
 
28 (4.3%) 
0.418 
Current cbs use 
Missing 
223 (34.2%) 
2 (0.3%) 
151 (23.1%) 
1 (0.2%) 
<0.001 
Lifetime DSM IV 
cbs Dependence 
Missing* 
 
247 (39.3%) 
26 (4.0%) 
 
58 (8.9%) 
3/654 (0.5%) 
 
<0.001 
Last 12 month 
DSM IV cbs 
 
96 (15.0%) 
 
12 (1.8%) 
 
 
Dependence <0.001 
Missing* 26 (5.2%) 3 (0.5%)  
Number of other 
drugs tried 
Missing 
 
1.47 
nil 
 
0.97 
nil 
 
<0.001 
Cigarettes/Roll-
ups per day† 
Missing* 
 
10.83 
19 (2.9%) 
 
4.42 
8 (1.2%) 
 
<0.001 
Units of alcohol 
per day† 
Missing 
 
5.14 
143 (21.8%) 
 
5.65 
88 (13.4%) 
0.251 
 
 
Legend: cbs: cannabis; Mean numbers (x̄ )are given unless specified as a proportion. 
Significance testing undertaken via 2-tailed independent t-tests for continuous variables and 
chi-squared tests for categorical variables. Missing data rates are italicised.  
 
* indicates significant difference (p<0.05) in missing data between cases and controls (chi 
squared test or Fisher’s exact test where any single value <=5).  
† Data was cleaned to remove outliers to max 40 cigarettes/day. Units of alcohol data 
cleaned to max of 30 units day  
Table 2 Primary Models for cannabis-induced Psychotic-Like Experiences 
caseness x extent of use interaction 
 
 
 (i) Model 1 – Frequency of cannabis use as a predictor F(4,1239.3)=33.65, p<0.001 
 b t p 
Frequency of cannabis use* 0.794 4.74 0.001 
Caseness† 1.354 6.20 <0.001 
Caseness x Frequency of use‡ 0.229 3.49 <0.001 
Cannabis-induced Euphoric Experiences 0.719 3.35 <0.001 
    
 (ii) Model 2 – Potency of cannabis as a predictor F(4,1141.9)=27.02, p<0.001 
 b t p 
Potency of cannabis* 1.241 2.28 0.023 
Caseness 0.142 0.42 0.676 
Caseness x Potency‡ 0.438 2.04 0.042 
Cannabis-induced Euphoric Experiences 0.114 6.43 0.016 
    
 (iii) Model 3 – Money spent  on cannabis as a predictor F(4,1235.8)=33.35, p<0.001 
 b t p 
Money spent on cannabis* 0.591 4.56 <0.001 
Caseness 0.267 1.59 0.112 
Caseness x Money spent on cannabis‡ 0.177 3.29 0.001 
Cannabis-induced Euphoric Experiences 0.084 4.35 <0.001 
    
 
Legend: 
Directions of effect as follows: *Increased extent predicts increased cPLEs; †First Episode Psychosis 
predicts increased cPLEs; ‡Significant caseness x extent interaction 
 
 
 
 
 
 
 
 
 
 
 
Figure	1:	Mean	cannabis-induced	Psychotic-like	Experiences	and	Euphoric	Experiences	
scores	by	case	and	control1	
	
(a-b)	Caseness	x	Frequency	of	cannabis	use	interaction	on	cannabis-induced	experiences:	
	
	 	
	
(c-d)	Caseness	x	Money	spent	on	cannabis	per	week	interaction	on	cannabis-induced	experiences:	
	
	 	
	
(e-f)	Caseness	x		Potency	of	cannabis	used	interaction	on	cannabis-induced	experiences	:	
	
																																																								
Legend: Light grey bars indicate First Episode Psychosis cases, dark grey bars for controls. Data drawn from complete 
case data. Y axis represents mean Psychotic Like Experiences and Euphoric Experiences scores +/- 95% Bootstrapped 
Confidence Interval.  
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sTable 1 DSM IV diagnosis of cases* (Operational Criteria Checklist 
(OPCRIT): 
  n % 
No diagnosis 69 10.3 
Major depressive disorder with 
psychosis 
56 8.4 
Manic episode with psychosis 58 8.7 
Schizophrenia 179 26.8 
Schizophreniform disorder 115 17.2 
Schizoaffective disorder, 
depressive type 
13 1.9 
Schizoaffective disorder, bipolar 
type 
19 2.8 
Delusional disorder 23 3.4 
Psychosis not otherwise 
specified (atypical psychosis) 
95 14.2 
Bipolar I disorder 20 3.0 
Missing 8 1.2 
Total 655*† 98.2*† 
 
*Ever cannabis using patients with FEP 
† Cases excluded from analysis (not shown in table above) were those with diagnosis of non 
psychotic disorders (n=12; 1.8%): Moderate Major depressive disorder; Major depressive 
disorder severe; hypomanic episode; Manic episode without psychosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 2	
 
sTable 2: Cases & Controls by site:  
 
 Total Case Control 
Brazil 
Ribeirão Preto 
  
89 (13.6%) 
 
60 (9.2%) 
 
149 (11.4%) 
     
France 
Val-de-Marne (Paris) 
Puy-de-Dôme 
(Clermont-Ferrand) 
 
  
31 (4.7%) 
 
38 (5.8%) 
 
69 (5.3%) 
 8 (1.2%) 23 (3.5%) 31 (2.4%) 
Holland 
Amsterdam 
 
Gouda and Voorhout  
  
86 (13.1%) 
 
69 (10.5%) 
 
64 (9.8%) 
 
57 (8.7%) 
 
150 (11.5%) 
 
126 (9.6%) 
    
Italy 
Bologna 
Palermo 
 
  
35 (5.3%) 
37 (5.6%) 
 
39 (6.0%) 
59 (9.0%) 
 
74 (5.7%) 
96 (7.3%) 
    
Spain 
Barcelona 
Cuenca 
Galicia 
Madrid 
Oviedo 
Valencia 
 
  
22 (3.4%) 
13 (2.0%) 
 
23 (3.5%) 
19 (2.9%) 
 
45 (3.4%) 
32 (2.4%) 
 19 (2.9%) 
29 (4.4%) 
21 (3.2%) 
29 (4.4%) 
24 (3.7%) 
19 (2.9%) 
21 (3.2%) 
16 (2.4%) 
43 (3.3%) 
48 (3.7%) 
42 (3.2%) 
45 (3.4%) 
United Kingdom  
Cambridge 
London 
 
  
29 (4.4%) 
138 (21.1%) 
 
51 (7.8%) 
141 (21.6%) 
 
80 (6.1%) 
279 (21.3%) 
    
Total  655 (100.0%) 654 (100.0%) 1321 (100.0%) 
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sTable 3: Cases & Controls by ethnicity 
 
 
  
Total Case Control 
 White  415 (63.4%) 547 (83.8%) 962 (73.5%) 
    
Black  105 (16.0%) 46 (7.0%) 151 (11.5%) 
    
Mixed  60 (9.2%) 31 (4.7%) 91 (7.0%) 
    
Asian  22 (3.4%) 12 (4.7%) 34 (2.6%) 
    
North 
African 
 31 (4.7%) 7 (1.1%) 38 (2.9%) 
    
Other  22 (3.4%) 10 (1.5%) 32 (2.4%) 
    
Total  655 (100.0%) 653 (99.8%)* 1308 (99.9%) 
    
 
 
 
*Ethnicity data for one control was missing. 
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sTable 4: Within item and between subscales correlations for Cannabis Experiences Questionnaire 
 
Fearful 1 
          Crazy, mad 0.5073 1 
         Nervy 0.4791 0.4349 1 
        Suspicious 0.5485 0.4574 0.4862 1 
       Hearing voices 0.2535 0.4047 0.2388 0.321 1 
      Seeing visions 0.2642 0.3829 0.1965 0.2619 0.4496 1 
     Feeling Happy -0.0201 0.0236 0.0454 0.1065 0.063 0.0532 1 
    Full of plans, ideas 0.0914 0.0984 0.1717 0.2809 0.1779 0.1639 0.4094 1 
   Undertanding the world better 0.1553 0.1084 0.1757 0.2709 0.1656 0.1655 0.3162 0.4857 1 
  cPLEs 0.7662 0.7558 0.7161 0.7848 0.5804 0.5397 0.0678 0.2379 0.2545 1 
 cEEs 0.0923 0.0972 0.1656 0.2747 0.1728 0.1619 0.7611 0.814 0.7516 0.2343 1 
 
           
 
Fearful 
C
razy, m
ad 
N
ervy 
S
uspicious 
H
earing voices 
S
eeing visions 
Feeling H
appy 
Full of plans, ideas 
U
ndertanding the w
orld better 
cP
LE
s 
cE
E
s 
Legend: cPLEs: Cannabis induced psychotic-like experiences; cEEs: Cannabis induced euphoric experiences, Pearson’s correlation coefficients colour coded (blue – 
minimal – red –maximal)
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sTable 5: Missing data rates 
 
 Case Controls 
Male 
 
nil nil 
White 
 
nil 1 (0.2%) 
Age at first contact  
 
 
nil 
 
Age at assessment  
 
 
nil 
 
1 (0.2%) 
Years in Education 
 
 
12 (1.8%) 
 
2 (0.3%) 
 
Age first tried cbs  
 
15 (2.2%) nil 
Frequency of cbs use 
 15 (2.3%) 1 (0.2%) 
Money Spent per week 
on cbs 61 (9.3%) 47 (7.2%) 
Use of high potency cbs 
 
 
131 (20.0%) 
 
136 (20.8%) 
Mean Duration of cbs 
use (years) 18 (2.7%) 28 (4.3%) 
Current cbs use 
 2 (0.3%) 1 (0.2%) 
Lifetime DSM IV cbs 
Dependence 26 (4.0%) 3/654 (0.5%) 
Last 12 month DSM IV 
cbs Dependence 26 (5.2%) 
3 (0.5%) 
 
Number of other drugs 
tried nil nil 
Cigarettes/Roll-ups per 
day 19 (2.9%) 8 (1.2%) 
Units of alcohol per day 
 
 
143 (21.8%) 
 
88 (13.4%) 
   
cPLEs 57 (8.7%) 39 (6.0%) 
cEEs 53 (8.1%) 38 (5.8%) 
 
 
Legend: cbs: cannabis; Bold typeface indicates significant difference (p<0.05) in missing 
data between cases and controls (chi squared test or Fisher’s exact test where any single 
value <=5).  
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sTable 6: Supplementary Analyses – cannabis frequency x status interaction regressing for substance type 
 
 
In the main analyses we had used ‘number of illicit substances ever tried’ as in order to control for illicit substance misuse. Reviewers had 
requested further analyses to control for different drug types as these may conceivable have different effects on cPLEs. We have therefore 
run a supplementary complete case analysis controlling for different drug types collected in the EU-GEI study: Inhalents, Crack, Cocaine, 
other Stimulants (such as amphetamines),  Sedatives, Opioids, Hallucinogens, Ketamine and Novel Psychoactive Stubstances. We have run 
two analyses – firstly controlling for ever use of these substances (coded 1 – ever having used and 0 – never having used) and secondly 
controlling for lifetime misuse (coded 1 – meeting DSM IV abuse or dependence criteria and 0 – not meeting criteria). 
 
sTable 6a: Prevelance of everuse and lifetime misuse by cases and controls 
 
 
	
Ever	Use	 Lifetime	misuse	
	
Case	 Control	 p-value	 Case	 Control	 p-value	
Inhalents	 92	(14.0%)	 50	(7.7%)	 <0.001	 9	(1.4%)	 2	(0.3%)	 0.064	
Crack	 56	(8.6%)	 24	(3.7%)	 <0.001	 21	(3.2%)	 9	(1.4%)	 0.0404	
Cocaine	 279	(42.6%)	 184	(28.1%)	 <0.001	 87	(13.3%)	 39	(6.0%)	 <0.001	
Stimulants	 203	(31.0%)	 150	(22.9%)	 0.001	 41	(6.3%)	 23	(3.5%)	 0.029	
Sedatives	 51	(7.8%)	 27	(4.1%)	 <0.001	 14	(2.1%)	 2	(0.3%)	 0.004	
Opioids	 46	(7.0%)	 19	(2.9%)	 <0.001	 19	(2.9%)	 5	(0.8%)	 0.006	
Hallucinogens	 142	(21.7%)	 118	(18.0%)	 0.111	 9	(1.4%)	 6	(0.9%)	 0.605	
Ketamine	 61	(9.3%)	 36	(5.5%)	 0.011	 5	(0.8%)	 1	(0.2%)	 0.217	
Novel	Psychoactive	Substances	 36	(5.5%)	 29	(4.4%)	 0.446	 9	(1.4%)	 3	(0.5%)	 0.144	
 
 
Legend: All tests cases versus control using Fisher’s exact test.  
Note all cases and controls in analysis limited to lifetime cannabis users in EUGEI study only.
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sTable 6b: Interaction of cannabis frequency x caseness on cPLEs regressing for illicit substance use 
 
 
 
 
 
  
Coefficient Standard Error t P>|t| 
 
Caseness 1.362 0.222 6.14 <0.001 
 
Frequency 0.798 0.172 4.63 <0.001 
 
Casenesss x Frequency 0.246 0.065 3.75 <0.001 
 
cEEs 0.134 0.044 3.04 0.002 
Li
fe
tim
e 
us
e 
Inhalents  0.713 0.454 1.57 0.116 
Crack 0.993 0.605 1.64 0.101 
Cocaine 0.123 0.276 0.45 0.654 
Stimulants 0.366 0.336 1.09 0.277 
Sedatives 1.034 0.578 1.79 0.074 
Opioids -0.545 0.595 -0.92 0.36 
Hallucinogens -0.370 0.311 -1.19 0.235 
Ketamine -0.423 0.412 -1.03 0.305 
Novel Psychoactive 
Substances -0.048 0.493 -0.1 0.922 
 
Constant 5.165 0.641 8.05 <0.001 
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sTable 6c: Interaction of cannabis frequency x caseness on cPLEs regressing for illicit substance misuse 
 
 
  
Coefficient Standard Error t P>|t| 
 
Caseness 1.381 0.229 6.03 <0.001 
 
Frequency 0.809 0.164 4.95 <0.001 
 
Casenesss x Frequency 0.250 0.070 3.58 <0.001 
 
cEEs 0.141 0.038 3.72 <0.001 
Li
fe
tim
e 
M
is
us
e 
Inhalents  3.226 1.179 2.74 0.006 
Crack 2.160 0.745 2.9 0.004 
Cocaine 0.139 0.402 0.35 0.729 
Stimulants 0.245 0.546 0.45 0.654 
Sedatives 2.399 0.974 2.46 0.014 
Opioids -1.619 0.840 -1.93 0.054 
Hallucinogens 0.627 1.001 0.63 0.531 
Ketamine -0.189 1.511 -0.13 0.9 
Novel Psychoactive 
Substances 1.361 1.175 1.16 0.247 
 
Constant 5.276 0.531 9.94 <0.001 
 
 
 
Consequently we observe that the findings of the main analysis remain the same when adjusting for other illicit substance confounders. 
Additionally we observe that a history of inhalents misuse, crack cocaine misuse are associated with increased cPLEs whereas opioid 
misuse appears associated with diminished cPLEs. This is broadly in keeping with previous literature in which whereas cannabis and 
cocaine use are synergistic for psychosis experiences1 whereas opiate withdrawal is associated with psychosis experiences2,3. However we 
note that overall numbers in the misuse groups for these substances are small (n<=30, see Table 6a) and such findings should be 
interpreted with caution. 
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